Continued Flow of Data Correlating Positive Clinical Improvements with CytoSorb® Usage
BRUSSELS, BELGIUM, March 16, 2016 – CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, announced the conclusion of its successful 3rd International CytoSorb Users Meeting in Brussels, Belgium. Held one day ahead of the International Symposium of Intensive Care and Emergency Medicine (ISICEM), one of the largest international critical care conferences, the Users Meeting brought together 107 members of the CytoSorb® community from a total of 23 countries, to share data from many new pre-clinical and clinical studies. To date, more than 10,000 CytoSorb® treatments have been performed in thousands of patients.
Some of the most important findings include:
Dr. Phillip Chan, Chief Executive Officer, stated,
“We are pleased to report this initial summary of the 3rd International CytoSorb® Users Meeting. The purpose of these meetings is to disseminate the lessons learned from experienced users so that we can ensure uniformity of treatment and that all users worldwide benefit from the latest information. Although there is always more to learn, we are pleased to see that when CytoSorb® is used in the right way, users continue to experience positive results with the treatment. As we have done in the past, a more detailed report of this meeting will be published in a proceedings booklet that will be available at our CytoSorb website.”
A comprehensive introduction on blood purification in general and on the CytoSorb therapy in particular, the underlying operating principle derived from preclinical data and its potential benefit in fighting life-threatening infections.
Overview on the evolution from a localized insult to life-threatening organ dysfunction caused by dysregulated host response, main conclusions from current CytoSorb evidence and data gained so far for the ACESS trial (Adsorbtion of Cytokines Early in Septic Shock)